reconstitution raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
| Property | Value | Notes |
|---|---|---|
| Purity determination | Reversed-phase HPLC | UV detection commonly at 214 nm |
| Mass confirmation | Mass spectrometry | Compared against theoretical 888.5 Da |
| Powder storage | -20 C or below | Dry and protected from light |
| Reconstituted storage | Aliquoted and frozen | Avoid repeated freeze-thaw cycles |
| Reconstitution solvent | Sterile water or neutral buffer | Avoid extreme pH conditions |
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
p53, dessen Aktivität als Transkriptionsfaktor durch Deacetylierung verringert wird, wodurch die Zell-Apoptose, die beispielsweise als Antwort auf DNA-Schaden oder oxidativen Stress erfolgt, hinausgezögert wird. Sirtuin-1 ist in der Lage, der Acetylierung von p53 durch den Tumorsuppressor PML entgegenzuwirken Forkhead-Box-Proteine, deren Deacetylierung parallel zu der von p53 die Apoptose verzögert. Zusätzlich wird durch Komplexbildung mit FOXO3 die Robustheit der Zelle gegen oxidativen Stress gestärkt das DNA-Reparaturprotein ku70, das den Apoptose-einleitenden Faktor bax absondert den Transkriptionsfaktor PGC1A, wodurch die Glukoneogenese und der Export von Glukose aus der Leber angekurbelt wird Histone 1, 3 und 4, die zumindest in der Bäckerhefe durch Sirtuin-1 deacetyliert wurden, um die Heterochromatin-Bildung einzuleiten Weiterhin wirkt Sirtuin-1 unter anderem durch direkte Bindung an
PPARγ, der selbst und dessen Kofaktoren Ncor und Smrt durch Sirtuin-1 im Hungerzustand gebunden werden, wodurch vermehrt Fette aus weißen Adipozyten mobilisiert werden. Gleichzeitig werden durch Sirtuin-1 die Neubildung von Fettzellen gestoppt und ausdifferenzierte Zellen lysiert. Allein die Lyse von Fettzellen ist bereits ausreichend, um die Lebensverlängerung bei Versuchen mit Mäusen zu erklären FOXO3 und p53 nur bei Hungersituation, wobei beide Faktoren und Hunger vorhanden sein müssen, damit Sirtuin-1 an PPARγ wirken kann. Das bedeutet, dass FOXO3, p53 und Sirtuin-1 zusammen ein System bilden, das auf Hungerzustand reagiert.
== Pharmakologie == Aufgrund der Wirkungen des Sirtuin-1 im Körper erscheint es sinnvoll, den Spiegel des Proteins bei bestehendem oder drohendem Diabetes mellitus Typ 2 zu erhöhen. Bisher standen dafür nur Empfehlungen zur Ernährung zur Verfügung, die besonders die bekannte Wirkung des Resveratrol betrafen. Seit 2007 stehen der Industrie Substanzen zu Gebot, die die aktivierende Wirkung des Resveratrol übertreffen. Insbesondere soll es sich bei der Substanz SRT1720 um eine Wirkungssteigerung um den Faktor 1000 handeln, was die tägliche Einnahme auf den Milligramm-Bereich reduzieren würde.
Die Migräne (wie französisch migraine über mittellateinisch hemigrania, einseitiger Kopfschmerz, von altgriechisch ἡμικρανία hēmikranía, deutsch ‚Kopfschmerz auf der einen Seite, Migräne‘, dieses von altgriechisch ἡμι hēmi, deutsch ‚halb‘ sowie altgriechisch κρανίον kraníon, deutsch ‚Hirnschale‘) ist eine neurologische Erkrankung, unter der rund 10 % der Bevölkerung leiden. Sie tritt bei Frauen etwa dreimal so häufig auf wie bei Männern, ist vor der Pubertät aber zwischen den Geschlechtern gleich verteilt und hat ein vielgestaltiges Krankheitsbild. Es ist bei Erwachsenen typischerweise gekennzeichnet durch einen periodisch wiederkehrenden, anfallartigen, meist pulsierenden und halbseitigen Kopfschmerz (eine Form der Neuralgie), der von zusätzlichen Symptomen wie Appetitlosigkeit, Übelkeit, Erbrechen, Blässe, Lichtempfindlichkeit (Photophobie) oder Geräuschempfindlichkeit (Phonophobie) begleitet sein kann. Bei manchen Patienten geht einem Migräneanfall (Migräneattacke) eine Migräneaura voraus, während der insbesondere optische oder sensible Wahrnehmungsstörungen auftreten. Es sind aber auch motorische Störungen möglich. Die Diagnose wird nach Ausschluss anderer Erkrankungen als Ursachen üblicherweise mit Hilfe einer Anamnese gestellt.
Sources: de.wikipedia.org
The lyophilised powder is typically held at -20 C or lower in a dry, dark place. Reconstituted solutions are aliquoted and frozen to avoid repeated freeze-thaw cycles.
Mass spectrometry is the usual confirmatory method because it measures the intact mass. Reversed-phase chromatography is used alongside it to estimate purity.
Not directly. Reported percentages depend on the chromatographic method, detection wavelength, and integration criteria, so the underlying method details matter.
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.